The present disclosure relates to methods for extending the shelf life of a sterile ophthalmic pharmaceutical composition.

The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.

The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.

This disclosure features compositions comprising niclosamide for use in treating one or more conditions (or one or more symptoms thereof) characterized by an abnormal inflammatory response in one or more particular subject (e.g., patient) populations in need thereof. Such conditions include, e.g., an autoimmune disorder, e.g., colitis, e.g., autoimmune colitis, e.g, an inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis. In some embodiments, the uses include rectally (e.g., via enema) administering niclosamide.

The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.

The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.

In one aspect, thermal energy storage compositions are described herein. In some embodiments, a composition comprises 0.5-10 wt. % polysaccharide and 88-99.5 wt. % water, wherein the weight percentages are based on the total weight of the composition. Moreover, in some cases, the composition is shape stable at 20° C. and 1 atm.